Cargando…
FDA initiatives to support dose optimization in oncology drug development: the less may be the better
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Society for Clinical Pharmacology and Therapeutics
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253446/ https://www.ncbi.nlm.nih.gov/pubmed/35800667 http://dx.doi.org/10.12793/tcp.2022.30.e9 |
| _version_ | 1784740487095123968 |
|---|---|
| author | Moon, Hanlim |
| author_facet | Moon, Hanlim |
| author_sort | Moon, Hanlim |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9253446 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Korean Society for Clinical Pharmacology and Therapeutics |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92534462022-07-06 FDA initiatives to support dose optimization in oncology drug development: the less may be the better Moon, Hanlim Transl Clin Pharmacol Commentary Korean Society for Clinical Pharmacology and Therapeutics 2022-06 2022-06-22 /pmc/articles/PMC9253446/ /pubmed/35800667 http://dx.doi.org/10.12793/tcp.2022.30.e9 Text en Copyright © 2022 Translational and Clinical Pharmacology https://creativecommons.org/licenses/by-nc/4.0/It is identical to the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/). |
| spellingShingle | Commentary Moon, Hanlim FDA initiatives to support dose optimization in oncology drug development: the less may be the better |
| title | FDA initiatives to support dose optimization in oncology drug development: the less may be the better |
| title_full | FDA initiatives to support dose optimization in oncology drug development: the less may be the better |
| title_fullStr | FDA initiatives to support dose optimization in oncology drug development: the less may be the better |
| title_full_unstemmed | FDA initiatives to support dose optimization in oncology drug development: the less may be the better |
| title_short | FDA initiatives to support dose optimization in oncology drug development: the less may be the better |
| title_sort | fda initiatives to support dose optimization in oncology drug development: the less may be the better |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253446/ https://www.ncbi.nlm.nih.gov/pubmed/35800667 http://dx.doi.org/10.12793/tcp.2022.30.e9 |
| work_keys_str_mv | AT moonhanlim fdainitiativestosupportdoseoptimizationinoncologydrugdevelopmentthelessmaybethebetter |